Can RNA edit­ing take At­las start­up where Ver­tex could­n't go? Ko­r­ro lands $116M to find out

As the CEO of RNA edit­ing start­up Ko­r­ro Bio, Ram Ai­yar of­ten gets the same ques­tion.

“I get al­ways asked, you know, if you can fix DNA, why both­er with RNA?” he told End­points News. “And it’s like ask­ing, which child do you pre­fer — your old­er one or your younger one?”

But in­vestors are ap­pre­ci­at­ing the dif­fer­ence. More than a year af­ter clos­ing its Se­ries A just shy of the megaround mark, Ko­r­ro Bio is back in the spot­light with $116 mil­lion in fresh cash and a lead can­di­date — tar­get­ing al­pha-1 an­tit­rypsin de­fi­cien­cy, or AATD.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER